Halozyme Therapeutics (NASDAQ:HALO) Director Sells $103,155.00 in Stock

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Director Bernadette Connaughton sold 1,625 shares of the business’s stock in a transaction on Friday, May 1st. The stock was sold at an average price of $63.48, for a total transaction of $103,155.00. Following the completion of the sale, the director owned 38,498 shares in the company, valued at approximately $2,443,853.04. The trade was a 4.05% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Halozyme Therapeutics Stock Down 1.7%

Shares of HALO stock opened at $65.19 on Friday. The stock has a market cap of $7.72 billion, a P/E ratio of 26.18, a PEG ratio of 0.27 and a beta of 0.89. Halozyme Therapeutics, Inc. has a 52 week low of $47.50 and a 52 week high of $82.22. The company has a quick ratio of 3.66, a current ratio of 4.66 and a debt-to-equity ratio of 43.89. The company’s fifty day simple moving average is $65.86 and its two-hundred day simple moving average is $68.59.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Tuesday, February 17th. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the consensus estimate of $1.92 by ($2.16). The company had revenue of $451.77 million during the quarter, compared to analysts’ expectations of $446.13 million. Halozyme Therapeutics had a return on equity of 136.12% and a net margin of 22.69%.The firm’s revenue for the quarter was up 51.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.26 EPS. Analysts predict that Halozyme Therapeutics, Inc. will post 7.68 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have commented on HALO shares. Wall Street Zen cut shares of Halozyme Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Saturday, February 21st. TD Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a research note on Wednesday, February 18th. HC Wainwright boosted their price target on shares of Halozyme Therapeutics from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Wednesday, April 29th. Weiss Ratings cut shares of Halozyme Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research note on Tuesday, February 24th. Finally, Wells Fargo & Company boosted their price target on shares of Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 19th. Six research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Halozyme Therapeutics has a consensus rating of “Hold” and an average target price of $79.11.

Institutional Trading of Halozyme Therapeutics

Hedge funds have recently made changes to their positions in the business. Root Financial Partners LLC purchased a new stake in shares of Halozyme Therapeutics during the 3rd quarter valued at about $25,000. Measured Wealth Private Client Group LLC grew its holdings in Halozyme Therapeutics by 51.5% during the 4th quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 124 shares during the last quarter. Larson Financial Group LLC grew its holdings in Halozyme Therapeutics by 3,118.2% during the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 343 shares during the last quarter. Richardson Financial Services Inc. grew its holdings in Halozyme Therapeutics by 87.6% during the 3rd quarter. Richardson Financial Services Inc. now owns 424 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 198 shares during the last quarter. Finally, Clearstead Advisors LLC grew its holdings in Halozyme Therapeutics by 107.7% during the 3rd quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company’s stock valued at $37,000 after purchasing an additional 265 shares during the last quarter. 97.79% of the stock is currently owned by hedge funds and other institutional investors.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.